Clinical trial
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
NCT00485498 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00485498 |
|---|---|
| Title | Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics |
| Official title | Managing Acute Schizophrenia, a Double Blind Comparison Between Two Atypical Antipsychotics - Olanzapine and Risperidone |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Olanzapine Hydrochloride, Risperidone |
| Enrollment | 122 |
| Start date | Apr 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 13, 2007 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: